Oncorena's FDA Green Light for Pioneering Renal Cancer Study
Oncorena Secures FDA Approval for Groundbreaking Study
Oncorena is excited to share that the FDA has granted approval for the Company’s IND application, allowing it to launch a Phase I/II clinical study known as Oncorella-1. This open-label, single-arm study aims to investigate the safety, tolerability, and efficacy of a promising treatment option using orellanine for patients suffering from metastatic clear-cell or papillary renal cell carcinoma.
Details of the Oncorella-1 Study
The Oncorella-1 study plans to enroll up to 75 patients who are grappling with severe metastatic renal cancer and are in need of dialysis. These individuals are in a particularly challenging situation, having exhausted standard treatment options. For them, ONC175 represents a ray of hope as a potential first-in-class therapeutic intervention to address their urgent medical needs.
This study will be taking place initially at a prominent institution, Karolinska University Hospital. Furthermore, plans are in place to conduct the study at the U.S. site, led by Professor Nizar Tannir, a recognized authority in renal cancer, at MD Anderson.
Insights from Oncorena's Leadership
Börje Haraldsson, the CEO and co-founder of Oncorena, expressed enthusiasm regarding this approval. He stated, "This approval brings us closer to evaluating the potential of this innovative treatment for patients who urgently need effective solutions. The launch of the U.S. site is a significant step forward for us." This enthusiasm underscores the urgent need for effective treatments in an area of significant medical need.
Understanding ONC175: A Novel Treatment
ONC175 is currently an investigational drug that features synthetically derived orellanine as its primary component. Orellanine has a unique mechanism of action highly specific to the kidneys, resulting in irreversible renal failure while sparing other organs. This specificity has been underlined in preclinical studies, showcasing ONC175's potential to effectively target and eradicate human metastatic renal cancer cells.
The mission behind developing ONC175 is to provide a potentially curative treatment for patients suffering from metastatic renal cell carcinoma who no longer have kidney function and are reliant on dialysis.
The Urgent Need for New Kidney Cancer Therapies
Globally, approximately 400,000 patients are diagnosed with kidney cancer each year, highlighting a significant public health challenge. Early detection can lead to successful surgical interventions; however, prognosis is considerably poorer for advanced metastatic cases. Although there are existing treatments, including targeted and immuno-therapeutic drugs, they typically do not result in cures, underscoring the pressing necessity for safe and effective new drugs in this space.
Company Contact Information
For further details, please reach out to Börje Haraldsson, M.D., Ph.D., who holds the positions of CEO and CSO at Oncorena AB. You may contact him via phone at +46 70 267 9544.
Frequently Asked Questions
What is the purpose of the Oncorella-1 study?
The Oncorella-1 study aims to evaluate the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients suffering from metastatic renal cancers.
Who can participate in the Oncorella-1 study?
The study will enroll up to 75 patients with severe metastatic renal cancer who require dialysis and have exhausted existing treatment options.
Where will the Oncorella-1 study take place?
The study will be conducted at Karolinska University Hospital and will also have sites in the U.S., including MD Anderson, led by Professor Nizar Tannir.
What is ONC175?
ONC175 is an investigational drug containing synthetically produced orellanine, which specifically targets kidney cancer cells with the aim of providing a potential cure.
Why is there a need for new kidney cancer treatments?
Current treatments often do not achieve cure rates, and there is a significant and urgent need for effective and safe therapies to improve outcomes for patients with advanced kidney cancer.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.